Key clinical point: Bimekizumab may be dosed every 8 weeks during maintenance therapy for plaque psoriasis in contrast to the 4-week dosing regimen typically adopted for anti-interleukin-17A biologics.

Major finding: The absolute change in Psoriasis Area Severity Index (PASI) at week 28 in patients receiving an additional bimekizumab dose vs placebo was −19.7 (95% CI, −24.2 to −15.2) vs −10.8 (95% CI, −13.5 to −8.0). Patients receiving placebo vs bimekizumab at week 16 showed a higher reduction in PASI 100 (−34.4% vs −11.7%) and Investigator's Global Assessment 0/1 (−62.5% vs 0.0%) response rates between weeks 16 and 28.

Study details: This was a prospective phase 2a study including 49 patients with moderate-to-severe plaque psoriasis who received bimekizumab at weeks 0 and 4 and were subsequently randomly assigned to receive either placebo or bimekizumab third dose at week 16.

Disclosures: The study was sponsored by UCB Pharma. Most of the authors including the lead author declared serving as employees of UCB Pharma, and some received research grants or consultation fees from various sources including UCB Pharma.

Source: Oliver R et al. Br J Dermatol. 2021 Oct 23. doi: 10.1111/bjd.20827.

Key clinical point: Bimekizumab may be dosed every 8 weeks during maintenance therapy for plaque psoriasis in contrast to the 4-week dosing regimen typically adopted for anti-interleukin-17A biologics.

Major finding: The absolute change in Psoriasis Area Severity Index (PASI) at week 28 in patients receiving an additional bimekizumab dose vs placebo was −19.7 (95% CI, −24.2 to −15.2) vs −10.8 (95% CI, −13.5 to −8.0). Patients receiving placebo vs bimekizumab at week 16 showed a higher reduction in PASI 100 (−34.4% vs −11.7%) and Investigator's Global Assessment 0/1 (−62.5% vs 0.0%) response rates between weeks 16 and 28.

Study details: This was a prospective phase 2a study including 49 patients with moderate-to-severe plaque psoriasis who received bimekizumab at weeks 0 and 4 and were subsequently randomly assigned to receive either placebo or bimekizumab third dose at week 16.

Disclosures: The study was sponsored by UCB Pharma. Most of the authors including the lead author declared serving as employees of UCB Pharma, and some received research grants or consultation fees from various sources including UCB Pharma.

Source: Oliver R et al. Br J Dermatol. 2021 Oct 23. doi: 10.1111/bjd.20827.

Key clinical point: Bimekizumab may be dosed every 8 weeks during maintenance therapy for plaque psoriasis in contrast to the 4-week dosing regimen typically adopted for anti-interleukin-17A biologics.

Major finding: The absolute change in Psoriasis Area Severity Index (PASI) at week 28 in patients receiving an additional bimekizumab dose vs placebo was −19.7 (95% CI, −24.2 to −15.2) vs −10.8 (95% CI, −13.5 to −8.0). Patients receiving placebo vs bimekizumab at week 16 showed a higher reduction in PASI 100 (−34.4% vs −11.7%) and Investigator's Global Assessment 0/1 (−62.5% vs 0.0%) response rates between weeks 16 and 28.

Study details: This was a prospective phase 2a study including 49 patients with moderate-to-severe plaque psoriasis who received bimekizumab at weeks 0 and 4 and were subsequently randomly assigned to receive either placebo or bimekizumab third dose at week 16.

Disclosures: The study was sponsored by UCB Pharma. Most of the authors including the lead author declared serving as employees of UCB Pharma, and some received research grants or consultation fees from various sources including UCB Pharma.

Source: Oliver R et al. Br J Dermatol. 2021 Oct 23. doi: 10.1111/bjd.20827.

Key clinical point: The novel calcipotriol (CAL)/betamethasone dipropionate (BDP) PAD-cream offered greater benefits than the currently available topical suspension/gel (CAL/BDP TS) in terms of efficacy and patient quality of life along with favorable safety in plaque psoriasis.

Major finding: At 8 weeks, CAL/BDP PAD-cream vs CAL/BDP TS was associated with a significantly higher Physician's Global Assessment success rate (43.2% vs 31.9%; P < .0001), mean percent reduction in modified Psoriasis Area Severity Index (64.6% vs 56.4%; P < .0001), and Dermatology Life Quality Index 0/1 response rate (43.8% vs 34.2%; P = .0005) and no adverse drug reaction with a frequency greater than 1%.

Study details: This is a pooled analysis of 2 phase 3 trials consisting of a combined 1,271 patients with mild-to-moderate plaque psoriasis, treated with either CAL/BDP PAD-cream (n=551), CAL/BDP TS (n=542), or vehicle (n=178).

Disclosures: Both trials were sponsored by MC2 Therapeutics, Denmark. Some of the authors including the lead author received investigator honoraria for phase 3 trials from MC2, and the rest are employees of MC2.

Source: Pinter A et al. J Eur Acad Dermatol Venereol. 2021 Oct 10. doi: 10.1111/jdv.17734.

Key clinical point: The novel calcipotriol (CAL)/betamethasone dipropionate (BDP) PAD-cream offered greater benefits than the currently available topical suspension/gel (CAL/BDP TS) in terms of efficacy and patient quality of life along with favorable safety in plaque psoriasis.

Major finding: At 8 weeks, CAL/BDP PAD-cream vs CAL/BDP TS was associated with a significantly higher Physician's Global Assessment success rate (43.2% vs 31.9%; P < .0001), mean percent reduction in modified Psoriasis Area Severity Index (64.6% vs 56.4%; P < .0001), and Dermatology Life Quality Index 0/1 response rate (43.8% vs 34.2%; P = .0005) and no adverse drug reaction with a frequency greater than 1%.

Study details: This is a pooled analysis of 2 phase 3 trials consisting of a combined 1,271 patients with mild-to-moderate plaque psoriasis, treated with either CAL/BDP PAD-cream (n=551), CAL/BDP TS (n=542), or vehicle (n=178).

Disclosures: Both trials were sponsored by MC2 Therapeutics, Denmark. Some of the authors including the lead author received investigator honoraria for phase 3 trials from MC2, and the rest are employees of MC2.

Source: Pinter A et al. J Eur Acad Dermatol Venereol. 2021 Oct 10. doi: 10.1111/jdv.17734.

Key clinical point: The novel calcipotriol (CAL)/betamethasone dipropionate (BDP) PAD-cream offered greater benefits than the currently available topical suspension/gel (CAL/BDP TS) in terms of efficacy and patient quality of life along with favorable safety in plaque psoriasis.

Major finding: At 8 weeks, CAL/BDP PAD-cream vs CAL/BDP TS was associated with a significantly higher Physician's Global Assessment success rate (43.2% vs 31.9%; P < .0001), mean percent reduction in modified Psoriasis Area Severity Index (64.6% vs 56.4%; P < .0001), and Dermatology Life Quality Index 0/1 response rate (43.8% vs 34.2%; P = .0005) and no adverse drug reaction with a frequency greater than 1%.

Study details: This is a pooled analysis of 2 phase 3 trials consisting of a combined 1,271 patients with mild-to-moderate plaque psoriasis, treated with either CAL/BDP PAD-cream (n=551), CAL/BDP TS (n=542), or vehicle (n=178).

Disclosures: Both trials were sponsored by MC2 Therapeutics, Denmark. Some of the authors including the lead author received investigator honoraria for phase 3 trials from MC2, and the rest are employees of MC2.

Source: Pinter A et al. J Eur Acad Dermatol Venereol. 2021 Oct 10. doi: 10.1111/jdv.17734.

Key clinical point: Abatacept-mediated CD28-CD80/CD86 blockade was inept at averting psoriasis relapse following ustekinumab withdrawal in patients with moderate-to-severe plaque psoriasis.

Major finding: Between weeks 12 and 88, abatacept vs ustekinumab groups displayed similar relapse rates (91.1% vs 87.0%; P = .41) and median time to relapse from the last dose of ustekinumab (36 weeks [95% CI, 36-48] vs 32 weeks [95% CI, 28-40]).

Study details: The data come from the PAUSE trial, including 91 adult patients with moderate-to-severe plaque psoriasis who achieved Psoriasis Area Severity Index 75 at week 12 of receiving ustekinumab and who were randomly assigned to either continued ustekinumab or switch to abatacept until week 39.

Disclosures: The study was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health and Eli Lilly and Co. Some of the authors declared receiving research/institutional grants and/or personal fees from various sources, including Eli Lilly.

Source: Harris KM et al. JAMA Dermatol. 2021 Oct 13. doi: 10.1001/jamadermatol.2021.3492.

Key clinical point: Abatacept-mediated CD28-CD80/CD86 blockade was inept at averting psoriasis relapse following ustekinumab withdrawal in patients with moderate-to-severe plaque psoriasis.

Major finding: Between weeks 12 and 88, abatacept vs ustekinumab groups displayed similar relapse rates (91.1% vs 87.0%; P = .41) and median time to relapse from the last dose of ustekinumab (36 weeks [95% CI, 36-48] vs 32 weeks [95% CI, 28-40]).

Study details: The data come from the PAUSE trial, including 91 adult patients with moderate-to-severe plaque psoriasis who achieved Psoriasis Area Severity Index 75 at week 12 of receiving ustekinumab and who were randomly assigned to either continued ustekinumab or switch to abatacept until week 39.

Disclosures: The study was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health and Eli Lilly and Co. Some of the authors declared receiving research/institutional grants and/or personal fees from various sources, including Eli Lilly.

Source: Harris KM et al. JAMA Dermatol. 2021 Oct 13. doi: 10.1001/jamadermatol.2021.3492.

Key clinical point: Abatacept-mediated CD28-CD80/CD86 blockade was inept at averting psoriasis relapse following ustekinumab withdrawal in patients with moderate-to-severe plaque psoriasis.

Major finding: Between weeks 12 and 88, abatacept vs ustekinumab groups displayed similar relapse rates (91.1% vs 87.0%; P = .41) and median time to relapse from the last dose of ustekinumab (36 weeks [95% CI, 36-48] vs 32 weeks [95% CI, 28-40]).

Study details: The data come from the PAUSE trial, including 91 adult patients with moderate-to-severe plaque psoriasis who achieved Psoriasis Area Severity Index 75 at week 12 of receiving ustekinumab and who were randomly assigned to either continued ustekinumab or switch to abatacept until week 39.

Disclosures: The study was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health and Eli Lilly and Co. Some of the authors declared receiving research/institutional grants and/or personal fees from various sources, including Eli Lilly.

Source: Harris KM et al. JAMA Dermatol. 2021 Oct 13. doi: 10.1001/jamadermatol.2021.3492.

Key clinical point: A significant improvement in overall survival is seen in chemotherapy-naïve Black vs White patients with metastatic castration-resistant prostate cancer (mCRPC) who received abiraterone or enzalutamide.

Major finding: The median follow-up was 19.0 and 18.7 months in Black and White patients, respectively. The overall survival was significantly longer in Black vs White patients (hazard ratio, 0.67; P <.0001).

Study details: A retrospective study of 2,910 patients with mCRPC from the Veterans Health Administration database who received enzalutamide or abiraterone after castration between April 2014 and March 2017.

Disclosures: This study was sponsored by Pfizer Inc. and Astellas Pharma, Inc. The authors received grants, personal/consulting fees, and nonfinancial support outside this work. Some authors were being employed and/or held stocks in various pharmaceutical companies.

Source: George DJ et al. Prostate Cancer Prostatic Dis. 2021 Nov 3. doi: 10.1038/s41391-021-00463-9.

Key clinical point: A significant improvement in overall survival is seen in chemotherapy-naïve Black vs White patients with metastatic castration-resistant prostate cancer (mCRPC) who received abiraterone or enzalutamide.

Major finding: The median follow-up was 19.0 and 18.7 months in Black and White patients, respectively. The overall survival was significantly longer in Black vs White patients (hazard ratio, 0.67; P <.0001).

Study details: A retrospective study of 2,910 patients with mCRPC from the Veterans Health Administration database who received enzalutamide or abiraterone after castration between April 2014 and March 2017.

Disclosures: This study was sponsored by Pfizer Inc. and Astellas Pharma, Inc. The authors received grants, personal/consulting fees, and nonfinancial support outside this work. Some authors were being employed and/or held stocks in various pharmaceutical companies.

Source: George DJ et al. Prostate Cancer Prostatic Dis. 2021 Nov 3. doi: 10.1038/s41391-021-00463-9.

Key clinical point: A significant improvement in overall survival is seen in chemotherapy-naïve Black vs White patients with metastatic castration-resistant prostate cancer (mCRPC) who received abiraterone or enzalutamide.

Major finding: The median follow-up was 19.0 and 18.7 months in Black and White patients, respectively. The overall survival was significantly longer in Black vs White patients (hazard ratio, 0.67; P <.0001).

Study details: A retrospective study of 2,910 patients with mCRPC from the Veterans Health Administration database who received enzalutamide or abiraterone after castration between April 2014 and March 2017.

Disclosures: This study was sponsored by Pfizer Inc. and Astellas Pharma, Inc. The authors received grants, personal/consulting fees, and nonfinancial support outside this work. Some authors were being employed and/or held stocks in various pharmaceutical companies.

Source: George DJ et al. Prostate Cancer Prostatic Dis. 2021 Nov 3. doi: 10.1038/s41391-021-00463-9.

Key clinical point: Androgen receptor amplification (ARamp) status is associated with clinical outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) who receive novel hormonal treatment (NHT) but not in those treated with taxanes.

Major finding: Patients with ARamp or PTEN aberrations (PTENalt) vs those without had worse relative PSA response with NHT vs taxanes. The presence of ARamp, PTENalt, or RB1 aberrations was associated with worse time to next treatment and overall survival with NHT without affecting clinical benefit from taxane therapy.

Study details: A retrospective study of 308 patients with mCRPC who received treatment between 2011 and 2020.

Disclosures: This work was sponsored by Foundation Medicine. Some authors disclosed employment with Foundation Medicine and/or stock ownership in Roche. The authors received speaker/consulting/ advisory fees, research funding, and/or honoraria outside this work.

Source: Graf RP et al. Eur Urol. 2021 Oct 26. doi: 10.1016/j.eururo.2021.09.030.

Key clinical point: Androgen receptor amplification (ARamp) status is associated with clinical outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) who receive novel hormonal treatment (NHT) but not in those treated with taxanes.

Major finding: Patients with ARamp or PTEN aberrations (PTENalt) vs those without had worse relative PSA response with NHT vs taxanes. The presence of ARamp, PTENalt, or RB1 aberrations was associated with worse time to next treatment and overall survival with NHT without affecting clinical benefit from taxane therapy.

Study details: A retrospective study of 308 patients with mCRPC who received treatment between 2011 and 2020.

Disclosures: This work was sponsored by Foundation Medicine. Some authors disclosed employment with Foundation Medicine and/or stock ownership in Roche. The authors received speaker/consulting/ advisory fees, research funding, and/or honoraria outside this work.

Source: Graf RP et al. Eur Urol. 2021 Oct 26. doi: 10.1016/j.eururo.2021.09.030.

Key clinical point: Androgen receptor amplification (ARamp) status is associated with clinical outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) who receive novel hormonal treatment (NHT) but not in those treated with taxanes.

Major finding: Patients with ARamp or PTEN aberrations (PTENalt) vs those without had worse relative PSA response with NHT vs taxanes. The presence of ARamp, PTENalt, or RB1 aberrations was associated with worse time to next treatment and overall survival with NHT without affecting clinical benefit from taxane therapy.

Study details: A retrospective study of 308 patients with mCRPC who received treatment between 2011 and 2020.

Disclosures: This work was sponsored by Foundation Medicine. Some authors disclosed employment with Foundation Medicine and/or stock ownership in Roche. The authors received speaker/consulting/ advisory fees, research funding, and/or honoraria outside this work.

Source: Graf RP et al. Eur Urol. 2021 Oct 26. doi: 10.1016/j.eururo.2021.09.030.

Key clinical point: Radical prostatectomy vs external beam radiotherapy (EBRT) is associated with significant improvement in cancer-specific mortality in patients with National Comprehensive Cancer Network (NCCN) high-risk and Johns Hopkins University (JH) very high-risk prostate cancer.

Major finding: Cancer-specific mortality (CSM) was significantly lower with radical prostatectomy vs EBRT in NCCN high-risk combined group (2.3% vs 4.1%; hazard ratio [HR], 0.68; P < .001) and JH very high-risk subgroup (3.5% vs 6.0%; HR, 0.58; P < .001). There was no significant difference in CSM between 2 treatments in JH high-risk patient subgroup (P = .2).

Study details: Study of 24,407 NCCN high-risk patients with prostate cancer identified from the Surveillance, Epidemiology, and End Results database between 2010 and 2016. Patients were subcategorized into JH high-risk and very high-risk groups.

Disclosures: No funding source was identified for this work. The authors declared no conflict of interests.

Source: Cheirigo F et al. J Urol. 2021 Sep 24. doi: 10.1097/JU.0000000000002250.

Key clinical point: Radical prostatectomy vs external beam radiotherapy (EBRT) is associated with significant improvement in cancer-specific mortality in patients with National Comprehensive Cancer Network (NCCN) high-risk and Johns Hopkins University (JH) very high-risk prostate cancer.

Major finding: Cancer-specific mortality (CSM) was significantly lower with radical prostatectomy vs EBRT in NCCN high-risk combined group (2.3% vs 4.1%; hazard ratio [HR], 0.68; P < .001) and JH very high-risk subgroup (3.5% vs 6.0%; HR, 0.58; P < .001). There was no significant difference in CSM between 2 treatments in JH high-risk patient subgroup (P = .2).

Study details: Study of 24,407 NCCN high-risk patients with prostate cancer identified from the Surveillance, Epidemiology, and End Results database between 2010 and 2016. Patients were subcategorized into JH high-risk and very high-risk groups.

Disclosures: No funding source was identified for this work. The authors declared no conflict of interests.

Source: Cheirigo F et al. J Urol. 2021 Sep 24. doi: 10.1097/JU.0000000000002250.

Key clinical point: Radical prostatectomy vs external beam radiotherapy (EBRT) is associated with significant improvement in cancer-specific mortality in patients with National Comprehensive Cancer Network (NCCN) high-risk and Johns Hopkins University (JH) very high-risk prostate cancer.

Major finding: Cancer-specific mortality (CSM) was significantly lower with radical prostatectomy vs EBRT in NCCN high-risk combined group (2.3% vs 4.1%; hazard ratio [HR], 0.68; P < .001) and JH very high-risk subgroup (3.5% vs 6.0%; HR, 0.58; P < .001). There was no significant difference in CSM between 2 treatments in JH high-risk patient subgroup (P = .2).

Study details: Study of 24,407 NCCN high-risk patients with prostate cancer identified from the Surveillance, Epidemiology, and End Results database between 2010 and 2016. Patients were subcategorized into JH high-risk and very high-risk groups.

Disclosures: No funding source was identified for this work. The authors declared no conflict of interests.

Source: Cheirigo F et al. J Urol. 2021 Sep 24. doi: 10.1097/JU.0000000000002250.

Key clinical point: Higher baseline serum levels of choline, betaine, and phenylacetylglutamine are associated with increased risk for incident lethal prostate cancer.

Major finding: Compared with the patients in the first quartile, the risk for incident lethal prostate cancer was higher in those with higher baseline levels of choline (odds ratio [OR] for third and fourth quartile, 2.37 and 2.19, respectively; P for trend = .005), betaine (OR for third and fourth quartile, 2.13 and 1.86, respectively; P for trend = .11), and phenylacetylglutamine (OR for third and fourth quartile, 2.54 and 2.55, respectively; P for trend = .003).

Study details: A study of 173 patients with lethal prostate cancer and 519 healthy individuals from the Prostate, Lung, Colorectal, and Ovarian Cancer Screening trial.

Disclosures: This study was supported by grants from National Cancer Institute and Prostate Cancer Foundation. The authors held patents and/or received consulting fees/research grants/royalties from various sources.

Source: Reichard CA et al. Cancer Epidemiol Biomarkers Prev. 2021 Oct 28. doi: 10.1158/1055-9965.

Key clinical point: Higher baseline serum levels of choline, betaine, and phenylacetylglutamine are associated with increased risk for incident lethal prostate cancer.

Major finding: Compared with the patients in the first quartile, the risk for incident lethal prostate cancer was higher in those with higher baseline levels of choline (odds ratio [OR] for third and fourth quartile, 2.37 and 2.19, respectively; P for trend = .005), betaine (OR for third and fourth quartile, 2.13 and 1.86, respectively; P for trend = .11), and phenylacetylglutamine (OR for third and fourth quartile, 2.54 and 2.55, respectively; P for trend = .003).

Study details: A study of 173 patients with lethal prostate cancer and 519 healthy individuals from the Prostate, Lung, Colorectal, and Ovarian Cancer Screening trial.

Disclosures: This study was supported by grants from National Cancer Institute and Prostate Cancer Foundation. The authors held patents and/or received consulting fees/research grants/royalties from various sources.

Source: Reichard CA et al. Cancer Epidemiol Biomarkers Prev. 2021 Oct 28. doi: 10.1158/1055-9965.

Key clinical point: Higher baseline serum levels of choline, betaine, and phenylacetylglutamine are associated with increased risk for incident lethal prostate cancer.

Major finding: Compared with the patients in the first quartile, the risk for incident lethal prostate cancer was higher in those with higher baseline levels of choline (odds ratio [OR] for third and fourth quartile, 2.37 and 2.19, respectively; P for trend = .005), betaine (OR for third and fourth quartile, 2.13 and 1.86, respectively; P for trend = .11), and phenylacetylglutamine (OR for third and fourth quartile, 2.54 and 2.55, respectively; P for trend = .003).

Study details: A study of 173 patients with lethal prostate cancer and 519 healthy individuals from the Prostate, Lung, Colorectal, and Ovarian Cancer Screening trial.

Disclosures: This study was supported by grants from National Cancer Institute and Prostate Cancer Foundation. The authors held patents and/or received consulting fees/research grants/royalties from various sources.

Source: Reichard CA et al. Cancer Epidemiol Biomarkers Prev. 2021 Oct 28. doi: 10.1158/1055-9965.

Key clinical point: Radical prostatectomy vs external beam radiotherapy (EBRT) is associated with lower cancer-specific mortality in African American patients with National Comprehensive Cancer Network (NCCN) high-risk and Johns Hopkins University (JH) very high-risk prostate cancer.

Major finding: Radical prostatectomy and EBRT were performed in 39% and 61% of patients, respectively. Radical prostatectomy vs EBRT was associated with lower risk for cancer-specific mortality at 5 years in NCCN high-risk (2.3% vs 3.9%; hazard ratio [HR], 0.52; P = .02) and JH very high-risk patients (3.3% vs 7.4%; HR, 0.42; P = .02).

Study details: A retrospective study of 4,165 NCCN high-risk African American patients with prostate cancer identified from the Surveillance, Epidemiology, and End Results database between 2010 and 2016. Patients were subcategorized into JH high-risk (n=1,944) and very high-risk (n=2,221) groups.

Disclosures: No funding source was identified for this work. The authors declared no conflict of interests.

Source: Hoeh B et al. Prostate. 2021 Oct 18. doi: 10.1002/pros.24253.

Key clinical point: Radical prostatectomy vs external beam radiotherapy (EBRT) is associated with lower cancer-specific mortality in African American patients with National Comprehensive Cancer Network (NCCN) high-risk and Johns Hopkins University (JH) very high-risk prostate cancer.

Major finding: Radical prostatectomy and EBRT were performed in 39% and 61% of patients, respectively. Radical prostatectomy vs EBRT was associated with lower risk for cancer-specific mortality at 5 years in NCCN high-risk (2.3% vs 3.9%; hazard ratio [HR], 0.52; P = .02) and JH very high-risk patients (3.3% vs 7.4%; HR, 0.42; P = .02).

Study details: A retrospective study of 4,165 NCCN high-risk African American patients with prostate cancer identified from the Surveillance, Epidemiology, and End Results database between 2010 and 2016. Patients were subcategorized into JH high-risk (n=1,944) and very high-risk (n=2,221) groups.

Disclosures: No funding source was identified for this work. The authors declared no conflict of interests.

Source: Hoeh B et al. Prostate. 2021 Oct 18. doi: 10.1002/pros.24253.

Key clinical point: Radical prostatectomy vs external beam radiotherapy (EBRT) is associated with lower cancer-specific mortality in African American patients with National Comprehensive Cancer Network (NCCN) high-risk and Johns Hopkins University (JH) very high-risk prostate cancer.

Major finding: Radical prostatectomy and EBRT were performed in 39% and 61% of patients, respectively. Radical prostatectomy vs EBRT was associated with lower risk for cancer-specific mortality at 5 years in NCCN high-risk (2.3% vs 3.9%; hazard ratio [HR], 0.52; P = .02) and JH very high-risk patients (3.3% vs 7.4%; HR, 0.42; P = .02).

Study details: A retrospective study of 4,165 NCCN high-risk African American patients with prostate cancer identified from the Surveillance, Epidemiology, and End Results database between 2010 and 2016. Patients were subcategorized into JH high-risk (n=1,944) and very high-risk (n=2,221) groups.

Disclosures: No funding source was identified for this work. The authors declared no conflict of interests.

Source: Hoeh B et al. Prostate. 2021 Oct 18. doi: 10.1002/pros.24253.

Key clinical point: Significant racial and ethnic disparities are reported in the use of prostate magnetic resonance imaging (MRI) following elevated prostate-specific antigen (PSA) test results.

Major finding: Black patients with PSA levels above 4 ng/mL and 10 ng/mL were 24.1% and 35.0% less likely to undergo subsequent prostate MRI, respectively, compared with White patients. Asian patients with PSA levels higher than 4 ng/mL were 24.1% less likely, and Hispanic patients with PSA levels above 10 ng/mL were 23.4% less likely to undergo subsequent prostate MRI than White patients.

Study details: A cohort study of 794,809 patients aged 40 years and above who received a single PSA result and no prior PSA screening or prostate MRI.

Disclosures: This work was supported by research funding from Harvey L. Neiman Health Policy Institute. Dr. Rosenkrantz reported employment with American Journal of Roentgenology. No other disclosures were reported.

Source: Abashidze N et al. JAMA Network Open. 2021 Nov 8. doi: 10.1001/jamanetworkopen.2021.32388.

Key clinical point: Significant racial and ethnic disparities are reported in the use of prostate magnetic resonance imaging (MRI) following elevated prostate-specific antigen (PSA) test results.

Major finding: Black patients with PSA levels above 4 ng/mL and 10 ng/mL were 24.1% and 35.0% less likely to undergo subsequent prostate MRI, respectively, compared with White patients. Asian patients with PSA levels higher than 4 ng/mL were 24.1% less likely, and Hispanic patients with PSA levels above 10 ng/mL were 23.4% less likely to undergo subsequent prostate MRI than White patients.

Study details: A cohort study of 794,809 patients aged 40 years and above who received a single PSA result and no prior PSA screening or prostate MRI.

Disclosures: This work was supported by research funding from Harvey L. Neiman Health Policy Institute. Dr. Rosenkrantz reported employment with American Journal of Roentgenology. No other disclosures were reported.

Source: Abashidze N et al. JAMA Network Open. 2021 Nov 8. doi: 10.1001/jamanetworkopen.2021.32388.

Key clinical point: Significant racial and ethnic disparities are reported in the use of prostate magnetic resonance imaging (MRI) following elevated prostate-specific antigen (PSA) test results.

Major finding: Black patients with PSA levels above 4 ng/mL and 10 ng/mL were 24.1% and 35.0% less likely to undergo subsequent prostate MRI, respectively, compared with White patients. Asian patients with PSA levels higher than 4 ng/mL were 24.1% less likely, and Hispanic patients with PSA levels above 10 ng/mL were 23.4% less likely to undergo subsequent prostate MRI than White patients.

Study details: A cohort study of 794,809 patients aged 40 years and above who received a single PSA result and no prior PSA screening or prostate MRI.

Disclosures: This work was supported by research funding from Harvey L. Neiman Health Policy Institute. Dr. Rosenkrantz reported employment with American Journal of Roentgenology. No other disclosures were reported.

Source: Abashidze N et al. JAMA Network Open. 2021 Nov 8. doi: 10.1001/jamanetworkopen.2021.32388.

Key clinical point: Prostrate-specific antigen (PSA) testing increased after the 2017 United States Preventive Services Task Force (USPSTF) draft statement for prostate cancer screening.

Major finding: A relative increase of 12.5% was seen in the PSA testing rate during 2016-2019. A relative increase of 10.1%, 12.1%, and 16.2% was seen in men aged 40-54 years, 55-69 years, and 70-89 years. A significantly increasing trend of PSA testing was seen after the release of USPSTF draft in April 2017 (0.30 tests per 100 person-years for each bimonthly period; P < .001).

Study details: This retrospective cohort study of 8,087,565 men aged 40 to 89 years who underwent prostate cancer screening between 2013 and 2019.

Disclosures: This work was funded by National Institutes of Health/National Cancer Institute. The authors received grants, honoraria, and consulting/personal/speaker fees from various sources.

Source: Leapman MS et al. JAMA Oncol. 2021 Nov 11. doi: 10.1001/jamaoncol.2021.5143.

Key clinical point: Prostrate-specific antigen (PSA) testing increased after the 2017 United States Preventive Services Task Force (USPSTF) draft statement for prostate cancer screening.

Major finding: A relative increase of 12.5% was seen in the PSA testing rate during 2016-2019. A relative increase of 10.1%, 12.1%, and 16.2% was seen in men aged 40-54 years, 55-69 years, and 70-89 years. A significantly increasing trend of PSA testing was seen after the release of USPSTF draft in April 2017 (0.30 tests per 100 person-years for each bimonthly period; P < .001).

Study details: This retrospective cohort study of 8,087,565 men aged 40 to 89 years who underwent prostate cancer screening between 2013 and 2019.

Disclosures: This work was funded by National Institutes of Health/National Cancer Institute. The authors received grants, honoraria, and consulting/personal/speaker fees from various sources.

Source: Leapman MS et al. JAMA Oncol. 2021 Nov 11. doi: 10.1001/jamaoncol.2021.5143.

Key clinical point: Prostrate-specific antigen (PSA) testing increased after the 2017 United States Preventive Services Task Force (USPSTF) draft statement for prostate cancer screening.

Major finding: A relative increase of 12.5% was seen in the PSA testing rate during 2016-2019. A relative increase of 10.1%, 12.1%, and 16.2% was seen in men aged 40-54 years, 55-69 years, and 70-89 years. A significantly increasing trend of PSA testing was seen after the release of USPSTF draft in April 2017 (0.30 tests per 100 person-years for each bimonthly period; P < .001).

Study details: This retrospective cohort study of 8,087,565 men aged 40 to 89 years who underwent prostate cancer screening between 2013 and 2019.

Disclosures: This work was funded by National Institutes of Health/National Cancer Institute. The authors received grants, honoraria, and consulting/personal/speaker fees from various sources.

Source: Leapman MS et al. JAMA Oncol. 2021 Nov 11. doi: 10.1001/jamaoncol.2021.5143.